| Title |
A prospective observational study of problematic oral cannabinoid use
|
|---|---|
| Published in |
Psychopharmacology, December 2017
|
| DOI | 10.1007/s00213-017-4811-6 |
| Pubmed ID | |
| Authors |
Mark A. Ware, Marc O. Martel, Roman Jovey, Mary E. Lynch, Joel Singer |
| Abstract |
Despite evidence supporting the benefits of cannabinoids for symptom control across a wide range of medical conditions, concerns have been raised regarding the potential misuse and/or problematic use of cannabinoids (CBs). The first objective of this study was to examine the incidence of problematic prescription cannabinoid use (PPCBU) over a 12-month period among patients initiating cannabinoid therapy. The second objective was to examine the factors associated with PPCBU. A total of 265 patients who were prescribed oral cannabinoid therapy as part of usual medical practice were enrolled into this prospective observational study. Patients first completed a series of baseline questionnaires assessing demographic, clinical, and substance use variables. Three measures designed to assess PPCBU were then administered at 3, 6, and 12 months after initiation of cannabinoid therapy. At each of the follow-up assessment time points, a significantly greater number of patients scored below (vs above) cutoff scores on the three main PPCBU outcomes (all p's < .001). At any follow-up time point, a maximum of roughly 25% of patients demonstrated PPCBU. Heightened odds of PPCBU were observed among patients with a history of psychiatric problems, tobacco smokers, and recreational cannabis users (all p's < .05). Results indicated that past-year substance abuse, assessed using the DAST-20, was the strongest predictor of PPCBU (p < .005). Findings from the present study could have implications for clinicians considering the use of cannabinoids for the management of patients with medical conditions. Although results indicated that the majority of patients included in this study did not reach cutoff scores on the three main PPCBU outcomes, our findings suggest that PPCBU should be routinely assessed and monitored over the course of cannabinoid therapy, particularly among patients with a history of psychiatric or substance use problems. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 2 | 33% |
| United States | 2 | 33% |
| Canada | 1 | 17% |
| Unknown | 1 | 17% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 33% |
| Scientists | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 71 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 17% |
| Researcher | 8 | 11% |
| Student > Bachelor | 8 | 11% |
| Professor | 5 | 7% |
| Student > Ph. D. Student | 5 | 7% |
| Other | 10 | 14% |
| Unknown | 23 | 32% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 20 | 28% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
| Psychology | 5 | 7% |
| Neuroscience | 4 | 6% |
| Nursing and Health Professions | 2 | 3% |
| Other | 7 | 10% |
| Unknown | 28 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 March 2024.
All research outputs
#3,394,340
of 24,620,470 outputs
Outputs from Psychopharmacology
#849
of 5,552 outputs
Outputs of similar age
#67,523
of 422,782 outputs
Outputs of similar age from Psychopharmacology
#16
of 41 outputs
Altmetric has tracked 24,620,470 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,552 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.3. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 422,782 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.